Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

co-primary endpoint was met. Relapse rates were lower with 24 weeks compared to 16 weeks of therapy (17.8 percent (29/163) and 16.3 percent (27/166) vs. 29.3 percent (49/167), respectively). Adverse events were similar, regardless of treatment duration or PEGINTRON dose.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

PEGINTRON is indicated for use in combination with REBETOL (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following points should be considered when initiating therapy with PEGINTRON in combination with REBETOL: (1) These indications are based on achieving undetectable HCV-RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. (2) Patients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. (3) No safety and efficacy data are available for treatment of longer than one year.

PEGINTRON is also indicated for use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age.

The following points should be considered when initiating therapy with PEGINTRON alone: Combination therapy w
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 of the ... Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced ... Background On 2 May 2013, Echo ... entire of the issued and to be issued share capital ... On 20 May 2013, Royalty Pharma announced the terms ...
(Date:5/23/2013)... SHENYANG, CHINA , May 24, 2013 /PRNewswire/ ... ("3SBio" or the "Company"), a leading ... developing, manufacturing and marketing biopharmaceutical products, announced today ... (the "EGM"), the Company,s shareholders voted in favor ... previously announced agreement and plan of merger dated ...
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... The Bill & Melinda Gates Foundation today announced that Dr. ... Health Program. Mundel, who is currently global head of development ... will start work at the foundation on December 1. ... to lead our global health program," said Bill Gates, co-chair ...
... Kan., Sept. 13, 2011 Bayer HealthCare LLC, Animal ... treatment system at its U.S. headquarters in Shawnee, Kan. ... one million gallons of water, or the equivalent of ... proprietary wastewater system began in early 2010 by CDI ...
Cached Medicine Technology:Gates Foundation Names Dr. Trevor Mundel to Lead Global Health Program 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 3Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 4
(Date:5/24/2013)... (PRWEB) May 24, 2013 A recent study ... of America dreads the upcoming bathing suit season. Almost 138 ... the weather heats up due to weight issues and a ... mercury rises. PharmaCo Labs recommends that those anxious about ... PhenObestin 37.5 as part of an overall effort to improve ...
(Date:5/24/2013)... myMEDholiday.com, a popular medical tourism portal which ... important medical travel destinations in Asia, has added a ... ensure a safe and successful trip for anyone planning ... tips on cost-savings, how to find the appropriate doctors ... wealth other essential advice. , A top-level marketing representative ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... May 24, 2013 This week is ... and their efforts to provide the best emergency care ... of this week is also to educate the public ... of survival. Citizens are the first link, and a ... proper bystander CPR after a cardiac arrest can triple ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
Breaking Medicine News(10 mins):Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2
... ... expertise in turnarounds and improving hospital profitability joins StatCom in a strategic partnership program that ... ... addition of Tom Brunelle FACHE, MBA, to the StatCom team. Previously Brunelle served as EVP ...
... , , , , , , , , ... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a leading China ... of the acquisition of buildings and land use,rights. The total consideration ... ), which will be financed from working capital. The,initial payment of ...
... ... connectivity combo solution to accelerate time-to-market for handset manufacturers to deliver interoperable sport, ... ... 15, 2010 -- ANT Wireless, a division of Dynastream Innovations Inc. (ANT) and ...
... ... has become the company’s Vice President of Product Services. Among his responsibilities, Randy will ... Notification Network, White Pine’s flagship personal health record solution. , ... (PRWEB) February 14, 2010 -- White ...
... ... Robert Lukasik has joined the company as Vice President of Sales. Separately, Kardea ... , ... 2010 -- Kardea Nutrition ™ LLC announced today that Robert Lukasik has joined the ...
... issue of the Journal of Clinical Sleep Medicine ... (OSA) report a significantly lower frequency of nightmares than ... OSA suppresses the cognitive experience of nightmare recall. ... nightmare recall decreased linearly as sleep apnea severity increased. ...
Cached Medicine News:Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 2Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 3Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 2Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 4Health News:Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services 2Health News:Kardea Nutrition Adds V.P. Sales, Extends Distribution Network 2Health News:Severe sleep apnea decreases frequency of nightmare recall 2
... This antimicrobial skin cleanser will not leave ... with frequent washings. With persistent Antimicrobial action, ... of microorganisms, including gram-negative and gram-positive bacteria, ... as a 15 second hand wash. The ...
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... Povidone Iodine Prep Pads ... surface pathogens including bacteria, ... yeast. Povidone Iodine is ... wounds or mucus membranes. ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: